Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
IDXX · Nasdaq · In Vitro & In Vivo Diagnostic Substances
Fundamental quality
85
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | $3,215M | $745M | $636M | $706M |
| 2022 | $3,367M | $679M | $394M | $657M |
| 2023 | $3,661M | $845M | $773M | $244M |
| 2024 | $3,898M | $888M | $808M | $329M |
| 2025 | $4,304M | $1,059M | $1,057M | $270M |
Between 2021 and 2025, revenue went from $3,215M to $4,304M (+34%) and net income went from $745M to $1,059M (+42%).
Annual figures in U.S. dollars per SEC filings. Net debt is total debt minus cash.
Is Idexx Laboratories Inc /De a profitable company?
Yes. Idexx Laboratories Inc /De shows a net margin of 24.6% and an ROE of 70.4%, a sign of a profitable business.
Does Idexx Laboratories Inc /De have a lot of debt?
Not particularly. Its net debt is 0.16 times its EBITDA, a low level.
Is Idexx Laboratories Inc /De growing?
Its revenue has grown 8.9% annualized in recent years and its earnings per share 15.9%.
Does Idexx Laboratories Inc /De generate cash?
Yes. It converts about 24.4% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Idexx Laboratories Inc /De cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →